Anika Therapeutics (ANIK) Operating Income (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Operating Income of $3.0 million for Q2 2026, up 170.67% year-over-year from $1.1 million in Q2 2025, and up 153.83% quarter-over-quarter from -$5.5 million in Q1 2026.
Anika Therapeutics (ANIK) Operating Income (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Operating Income for 17 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Income rose 170.67% year-over-year to $3.0 million; the TTM figure through Jun 2026 stood at -$5.1 million (up 44.64% YoY), while the FY2025 annual figure was -$11.1 million, down 116.64% from the prior year.
- Operating Income advanced to $3.0 million in Q2 2026 per ANIK's latest filing, from -$5.5 million in the prior quarter.
- Across five years, Operating Income topped out at $24.7 million in Q4 2023 and bottomed at -$12.6 million in Q1 2023.
- Historically, Operating Income has averaged -$787333.3 across 5 years, with a median of -$3.3 million in 2022.
- Annual changes were most pronounced in 2022 — Operating Income soared 279.8% — and 2025, when it plunged 3891.36%.
- Anika Therapeutics' Operating Income stood at $16.4 million in 2022, then surged by 50.59% to $24.7 million in 2023, then slumped by 102.85% to -$705000.0 in 2024, then surged by 191.63% to $646000.0 in 2025, then surged by 357.28% to $3.0 million in 2026.
- Business Quant data shows ANIK's Operating Income at $3.0 million in Q2 2026, -$5.5 million in Q1 2026, and $646000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | 2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.95 Mn |
| Mar 31, 2026 | -5.49 Mn |
| Dec 31, 2025 | 646,000.00 |
| Sep 30, 2025 | -3.23 Mn |
| Jun 30, 2025 | -4.18 Mn |
| Mar 31, 2025 | -4.28 Mn |
| Dec 31, 2024 | -705,000.00 |
| Sep 30, 2024 | -81,000.00 |
| Jun 30, 2024 | -1.81 Mn |
| Mar 31, 2024 | -2.51 Mn |
| Dec 31, 2023 | 24.70 Mn |
| Sep 30, 2023 | -7.67 Mn |
| Jun 30, 2023 | -3.63 Mn |
| Mar 31, 2023 | -12.55 Mn |
| Dec 31, 2022 | 16.40 Mn |
| Sep 30, 2022 | -5.80 Mn |
| Jun 30, 2022 | -3.38 Mn |
| Mar 31, 2022 | -3.55 Mn |
| Dec 31, 2021 | -9.12 Mn |
| Sep 30, 2021 | 1.30 Mn |